Physician profile
Aaron M Brewer
NPI 1033306709
$10,149.92
in general payments reported to CMS, 2019-2025
27 companies · $1,052 in 2025
The $1,052 reported for 2025 was more than what 91% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,974 · 2020: $697 · 2021: $2,179 · 2022: $1,376 · 2023: $1,294 · 2024: $1,578 · 2025: $1,052.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,924.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,924.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $2,080.88 | 2022-2025 | Infuse, Miebo, Xiidra |
| Alcon Vision LLC | $1,842.28 | 2019-2025 | Precision 1, Total30, Tryptyr |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $1,339.43 | 2019-2021 | |
| Allergan, INC. | $885.73 | 2019-2022 | |
| Glaukos Corporation | $796.15 | 2019-2024 | Radius |
| Coopervision INC. | $546.03 | 2021-2025 | Myday Contact Lens, Cvi Contact Lens, Misight Contact Lens |
| Abbvie INC. | $397.02 | 2022-2025 | |
| Johnson & Johnson Surgical Vision, INC. | $255.61 | 2024-2025 | Tecnis Simplicity, Tecnis Iol |
| Sun Pharmaceutical Industries INC. | $242.55 | 2019-2023 | Cequa |
| Tarsus Pharmaceuticals, INC. | $195.20 | 2024-2025 | Xdemvy |
| Dompe US, INC. | $193.50 | 2023-2025 | Oxervate |
| Lombart Brothers, INC. | $190.02 | 2021-2024 | Opd-III |
| Lkc Technologies, INC. | $180.94 | 2022-2023 | |
| Oyster Point Pharma, INC. | $176.37 | 2022-2024 | Tyrvaya |
| Eyevance Pharmaceuticals LLC | $164.59 | 2019-2021 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sight Sciences, INC. | $143.99 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $118.99 | 2019-2023 | |
| Kala Pharmaceuticals, INC. | $84.74 | 2021-2022 | |
| Astellas Pharma US INC | $69.42 | 2024-2025 | Izervay |
| Staar Surgical Company | $47.96 | 2019 | |
| Shire North American Group INC | $47.83 | 2019 | |
| Aerie Pharmaceuticals, INC. | $41.29 | 2019-2021 | |
| Carl Zeiss Meditec USA, INC. | $27.06 | 2021 | |
| Harrow Eye, LLC | $24.25 | 2025 | Vevye |
| Maculogix, INC. | $20.55 | 2021 | |
| Carl Zeiss Meditec Ag | $19.40 | 2020 | |
| Lumenis, INC | $18.14 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aaron Brewer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.